Cosmo Pharmaceuticals N.V. (COPN.SW) announced the renewal of its multi-year manufacturing and supply agreement with Takeda.
As per the deal, Cosmo will continue producing Mesalazine MMX 1200 mg—marketed as Lialda in the USA and Mezavant in Europe—a once-daily oral treatment for ulcerative colitis.
Cosmo's advanced manufacturing site in Lainate (Italy) is approved by multiple regulatory authorities worldwide.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.